Kymera Therapeutics, Inc. (KYMR)
Develops drugs that destroy disease-causing proteins using the body's natural cleanup system.
$107.48-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+150.2%
The outlook
KYMR is trading near the upper end of its 52-week range, comfortably above both short- and long-term moving averages. Analyst consensus is strongly bullish, with an average price target sitting roughly 18% above the current price. The stock shows solid upward momentum in its recent trend.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 21 analysts
Price trendAbove its 50- & 200-day averages
52-week range76% of the way from its 52-week low to high
Price targetAvg target +18% vs current price
Analyst price target
~12-month · 21 analysts$127.05average target+18.2% vs now
Now $107.48
Low $97.00High $155.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.84B
52-wk high
$130.05
52-wk low
$36.65
50-day avg
$96.12
200-day avg
$81.21
Trailing P/E
—